CARDIOPROTECTIVE EFFECT OF TRIPLE THERAPY FOR HYPERTENSION

Download full text PDF
Issue: 
3
Year: 
2017

L. Khafizova, Candidate of Medical Sciences; G. Khamidullaeva, MD Republican Specialized Center of Cardiology, Tashkent, Uzbekistan

Analysis of three-component therapy with amlodipine, indapamide, and renin-angiotensin system blockers allows it to be considered as optimal in reducing the risk of cardiovascular events in most hypertensive patients.
Keywords: 
cardiology
essential hypertension
combined antihypertensive therapy

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. The MRFIT research group. Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results // JAMA. – 1982; 248: 1465–77.
  2. Diagnostika i lechenie arterial'noj gipertenzii. Rekomendatsii VNOK (tretij peresmotr) // Kardiovask. ter. i profilakt. – 2008; 7 (Pril. 2): 31.
  3. Sesso H., Rosner M., Hennekens C. et al. Systolic and diastolic blood pressure, pulse pressure and mean arterial pressure as predictors of cardiovascular disease risk in men // Hypertension. – 2000; 36: 801–7.
  4. Shljahto E.V., Kondri A.O. Strukturno-funktsional'nye izmenenija miokarda u bol'nyh gipertonicheskoj bolezn'ju // Kardiologija. – 1999; 6: 78–82.
  5. Hafizova L.Sh., Hamidullaeva G.A. Vlijanie trehmesjachnoj kombinirovannoj terapii indapamida s lerkanidipinom na parametry vnutriserdechnoj gemodinamiki // Tsentral'no-Aziatskij meditsinskij zhurnal. – 2014; tom 20 (4): 271–5.
  6. Aznaouridis K., Stamatelopoulos K.S, Karatzis E. et al. Acute effects of renin-angiotensin system blockade on arterial function in hypertensive patients // J. Hum. Hypertens. – 2007; 21: 654–63.
  7. Hansson L., Zanchetti A. The Hypertension Optimal Treatment study (The HOT Study) – patient characteristics: randomization, risk profiles, and early blood pressure results // Blood Press. – 1994; 3: 322–7.
  8. Grachev A.V. Tsentral'nye i perifericheskie mehanizmy adaptatsii serdechno-sosudistoj sistemy u bol'nyh arterial'noj gipertoniej (patogeneticheskie i terapevticheskie aspekty). Dis. ... d-ra med. nauk. Tashkent, 2001; 364 s.
  9. The Task Force for the Management of Arterial Hypertension of the ESH and ESC // J. Hypertens. – 2013; 31 (7): 1281–357.
  10. Savage D., Garrison R., Kannel W. et al. The spectrum of left ventricular hypertrophy in a general population sample: The Framingham Study // Circulation. – 1987; 75: 26.
  11. Borgi C., Morbini M., Cicero A. Combination therapy in the extended cardiovascular continuum: a focus on perindopril and amlodipine // J. Cardiovasc. Med. – 2015; 16.
  12. Kalman Toth on behalf of PIANIST investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST Study // Am. J. Cardiovasc. Drugs. – 2014; 14: 137–45.
  13. Jamerson K., Weber M., Bakris G. et al. Benazepril plus amlodipine or hydrochlortiazide for hypertension in high risk patients // N. Engl. J. Med. – 2008; 359: 2417–28.
  14. Fagard R., Cells H., Thijs L. et al. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies // Hypertension. – 2009; 54: 1084–91.
  15. Devereux R., Wachtell K., Gerdts E. et al. Prognostic significance of left ventricular mass change during treatment of hypertension // JAMA. – 2004; 292: 2350–6.
  16. Dahlof B., Devereux R., Julius S. et al. Characteristics of 9194 patients with left ventricular hypertrophy. The LIFE Study // Hypertension. – 1998; 32: 989–97.